Why the study?
Heart failure prevention is an urgent public health need, yet Stage A patients are heterogeneous and lack unique recommendations for detection.
Comprehensive strategies including lifestyle modifications, risk factor management, and early biomarker/imaging use are essential for primordial and primary prevention of heart failure in Stage A patients.
No takes yet. Share an insight, caveat, or question.
May inform early HF prevention strategies in Stage A; leaves open prospective trials on biomarker/imaging integration.
Upadhya et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: